Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?

被引:8
作者
Infante, Mar [1 ]
Arranz-Ledo, Monica [1 ]
Lastra, Enrique [2 ]
Abella, Luis Enrique [3 ]
Ferreira, Raquel [3 ]
Orozco, Marta [3 ]
Hernandez, Lara [1 ]
Martinez, Noemi [1 ]
Duran, Mercedes [1 ]
机构
[1] Univ Valladolid Spanish, Excellence Unit Inst Biol & Mol Genet, UVa CSIC, Canc Genet Grp,Natl Res Council IBGM, C Sanz & Fores 3, Valladolid 47003, Spain
[2] Burgos Univ Hosp, Unit Genet Counseling Canc, Burgos 09006, Spain
[3] Rio Hortega Univ Hosp, Unit Genet Counseling Canc, Valladolid 47012, Spain
关键词
Hereditary Breast and Ovarian Cancer Syndrome (HBOC); Lynch Syndrome (LS); multi-gene panel testing; double heterozygotes; genetic counseling; FAMILIAL BREAST; MUTATIONS; RAD51C; BRCA1;
D O I
10.3390/ijms231911499
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The probability of carrying two pathogenic variants (PVs) in dominant cancer-predisposing genes for hereditary breast and ovarian cancer and lynch syndromes in the same patient is uncommon, except in populations where founder effects exist. Two breast cancer women that are double heterozygotes (DH) for both BRCA1/BRCA2, one ovarian cancer case DH for BRCA1/RAD51C, and another breast and colorectal cancer who is DH for BRCA2/PMS2 were identified in our cohort. Ages at diagnosis and severity of disease in BRCA1/BRCA2 DH resembled BRCA1 single-carrier features. Similarly, the co-existence of the BRCA2 and PMS2 mutations prompted the development of breast and colorectal cancer in the same patient. The first BRCA1/BRCA2 DH was identified by HA-based and Sanger sequencing (1 of 623 families with BRCA PVs). However, this ratio has increased up to 2.9% (1 DH carrier vs. 103 single PV carriers) since using a custom 35-cancer gene on-demand panel. The type of cancer developed in each DH patient was consistent with the independently inherited condition, and the clinical outcome was no worse than in patients with single BRCA1 mutations. Therefore, the clinical impact, especially in patients with two hereditary syndromes, lies in genetic counseling tailor-made for each family based on the clinical guidelines for each syndrome. The number of DH is expected to be increased in the future as a result of next generation sequencing routines.
引用
收藏
页数:12
相关论文
共 50 条
[31]   The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice [J].
Menko, Fred H. ;
ter Stege, Jacqueline A. ;
van der Kolk, Lizet E. ;
Jeanson, Kiki N. ;
Schats, Winnie ;
Moha, Daoud Ait ;
Bleiker, Eveline M. A. .
FAMILIAL CANCER, 2019, 18 (01) :127-135
[32]   Targeted Therapy for Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Adenomatous Polyposis, and Li-Fraumeni Syndrome [J].
Agarwal, Rishi ;
Liebe, Sarah ;
Turski, Michelle L. ;
Vidwans, Smruti J. ;
Janku, Filip ;
Garrido-Laguna, Ignacio ;
Munoz, Javier ;
Schwab, Richard ;
Rodon, Jordi ;
Kurzrock, Razelle ;
Subbiah, Vivek .
DISCOVERY MEDICINE, 2014, 18 (101) :331-339
[33]   Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History [J].
Patel, Aniruddh P. ;
Wang, Minxian ;
Fahed, Akl C. ;
Mason-Suares, Heather ;
Brockman, Deanna ;
Pelletier, Renee ;
Amr, Sami ;
Machini, Kalotina ;
Hawley, Megan ;
Witkowski, Leora ;
Koch, Christopher ;
Philippakis, Anthony ;
Cassa, Christopher A. ;
Ellinor, Patrick T. ;
Kathiresan, Sekar ;
Ng, Kenney ;
Lebo, Matthew ;
Khera, Amit, V .
JAMA NETWORK OPEN, 2020, 3 (04)
[34]   Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families [J].
Vicuña B. ;
Delaney H.D. ;
Flores K.G. ;
Ballinger L. ;
Royce M. ;
Dayao Z. ;
Pal T. ;
Kinney A.Y. .
Journal of Community Genetics, 2018, 9 (1) :81-92
[35]   Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer [J].
Clark, Dana Farengo ;
Michalski, Scott T. ;
Tondon, Rashmi ;
Nehoray, Bita ;
Ebrahimzadeh, Jessica ;
Hughes, Sarah Kate ;
Soper, Emily R. ;
Domchek, Susan M. ;
Rustgi, Anil K. ;
Pineda-Alvarez, Daniel ;
Anderson, Michael J. ;
Katona, Bryson W. .
GENETICS IN MEDICINE, 2020, 22 (05) :840-846
[36]   Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy [J].
Rizzolo, Piera ;
Zelli, Veronica ;
Silvestri, Valentina ;
Valentini, Virginia ;
Zanna, Ines ;
Bianchi, Simonetta ;
Masala, Giovanna ;
Spinelli, Alessandro Mauro ;
Tibiletti, Maria Grazia ;
Russo, Antonio ;
Varesco, Liliana ;
Giannini, Giuseppe ;
Capalbo, Carlo ;
Calistri, Daniele ;
Cortesi, Laura ;
Viel, Alessandra ;
Bonanni, Bernardo ;
Azzollini, Jacopo ;
Manoukian, Siranoush ;
Montagna, Marco ;
Peterlongo, Paolo ;
Radice, Paolo ;
Palli, Domenico ;
Ottini, Laura .
INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (02) :390-400
[37]   Prevalence and Distribution of Unexpected Actionable Germline Pathogenic Variants Identified on Broad-Based Multigene Panel Testing Among Patients With Cancer [J].
Landry, Kara K. ;
Desarno, Michael J. ;
Kipnis, Lindsay ;
Barquet Ramos, Farid ;
Breen, Katelyn M. ;
Patton, Kaleigh ;
Morrissette, Audrey ;
Buehler, Ryan M. ;
Ukaegbu, Chinedu ;
Rohanizadegan, Mersedeh ;
Yurgelun, Matthew B. ;
Syngal, Sapna ;
Rana, Huma Q. ;
Garber, Judy E. .
JCO PRECISION ONCOLOGY, 2024, 8
[38]   Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector [J].
van der Merwe, Nerina C. ;
Ntaita, Kholiwe S. ;
Stofberg, Hanri ;
Combrink, Herkulaas MvE. ;
Oosthuizen, Jaco ;
Kotze, Maritha J. .
FRONTIERS IN ONCOLOGY, 2022, 12
[39]   Retrospective Study of Genetic Testing Results Reveals Pathogenic Variants Beyond BRCA1/2 in Hereditary Breast and Ovarian Cancer Cases in New Brunswick: Implications for Future Care [J].
Gauvin, Kelly ;
Allain, Veronique ;
Bouhamdani, Nadia ;
Williams, Chloe ;
Saheb, Yanis ;
Savoie, Catherine ;
Macrae, Lynn ;
Hodson, Katherine ;
Zhu, Yun Amber ;
Allain, Eric ;
Amor, Mouna Ben .
CANCER MEDICINE, 2025, 14 (03)
[40]   Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system [J].
Powell, C. Bethan ;
Laurent, Cecile ;
Garcia, Christine ;
Hoodfar, Elizabeth ;
Karlea, Audrey ;
Kobelka, Christine ;
Lee, Jaimie ;
Roh, Janise ;
Kushi, Lawrence H. .
CLINICAL GENETICS, 2022, 101 (03) :324-334